We are live on
!
Find out more
AA
ALPS Advisors Portfolio holdings
AUM
$21.3B
1-Year Est. Return
21.71%
This Fund
S&P 500
This Quarter
Est. Return
-11.26%
1 Year Est. Return
+21.71%
3 Year Est. Return
+77.63%
5 Year Est. Return
+121.1%
10 Year Est. Return
+198.29%
AUM
$10.3B
AUM Growth
+$1.07B
(+12%)
Cap. Flow
+$2.36B
Cap. Flow
% of AUM
22.99%
Top 10 Holdings %
Top 10 Hldgs %
47.42%
Holding
1,109
New
276
Increased
252
Reduced
500
Closed
79
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Western Midstream Partners
WES
|
+$619M |
| 2 |
Cameco
CCJ
|
+$146M |
| 3 |
Hess Midstream
HESM
|
+$80.6M |
| 4 |
Verizon
VZ
|
+$58.6M |
| 5 |
Microsoft
MSFT
|
+$51.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Energy Transfer Partners
ET
|
+$71M |
| 2 |
Enterprise Products Partners
EPD
|
+$30.3M |
| 3 |
PBCT
People's United Financial Inc
PBCT
|
+$23.8M |
| 4 |
REGI
Renewable Energy Group, Inc.
REGI
|
+$20.4M |
| 5 |
ENLC
ENLINK MIDSTREAM, LLC
ENLC
|
+$16.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 60.43% |
| 2 | Technology | 6.16% |
| 3 | Healthcare | 4.82% |
| 4 | Consumer Discretionary | 4.16% |
| 5 | Industrials | 3.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Viridian Therapeutics
VRDN
$2.13B
| $192K | ﹤0.01% |
+16,560
| New | +$223K |
|
1002
Transocean
RIG
$5.92B
| $191K | ﹤0.01% |
+57,475
| New | +$233K |
|
1003
Seres Therapeutics
MCRB
$48M
| $188K | ﹤0.01% |
2,736
-1,993
| -42% | -$172K |
|
1004
MoonLake Immunotherapeutics
MLTX
$1.59B
| $164K | ﹤0.01% |
+31,260
| New | +$196K |
|
|
ADAP
1005
DELISTED
Adaptimmune Therapeutics
ADAP
| $163K | ﹤0.01% |
+96,110
| New | +$165K |
|
|
AUTL
1006
Autolus Therapeutics
AUTL
$386M
| $153K | ﹤0.01% |
53,931
-39,502
| -42% | -$120K |
|
|
WHWK
1007
Whitehawk Therapeutics
WHWK
$183M
| $153K | ﹤0.01% |
12,423
-9,046
| -42% | -$134K |
|
1008
Archrock
AROC
$6.33B
| $152K | ﹤0.01% |
18,398
+2,310
| +14% | +$21.2K |
|
|
KLRS
1009
Kalaris Therapeutics
KLRS
$88.7M
| $151K | ﹤0.01% |
1,687
-1,233
| -42% | -$129K |
|
1010
SunCoke Energy
SXC
$757M
| $145K | ﹤0.01% |
21,348
+2,153
| +11% | +$17.4K |
|
1011
Rallybio
RLYB
$86.6M
| $144K | ﹤0.01% |
+2,383
| New | +$179K |
|
1012
CoreCivic
CXW
$3.1B
| $143K | ﹤0.01% |
12,906
+1,658
| +15% | +$20K |
|
|
KALV
1013
DELISTED
KalVista Pharmaceuticals
KALV
| $143K | ﹤0.01% |
14,561
-10,658
| -42% | -$118K |
|
|
LIAN
1014
DELISTED
LianBio American Depositary Shares
LIAN
| $139K | ﹤0.01% |
64,228
-45,991
| -42% | -$156K |
|
1015
Aldeyra Therapeutics
ALDX
$91.7M
| $138K | ﹤0.01% |
34,581
-25,125
| -42% | -$86.4K |
|
|
ICVX
1016
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $135K | ﹤0.01% |
+23,565
| New | +$184K |
|
1017
EverQuote
EVER
$886M
| $134K | ﹤0.01% |
+15,169
| New | +$173K |
|
1018
4D Molecular Therapeutics
FDMT
$526M
| $134K | ﹤0.01% |
+19,155
| New | +$186K |
|
|
ZYXI
1019
DELISTED
Zynex
ZYXI
| $127K | ﹤0.01% |
+15,855
| New | +$112K |
|
|
VBIV
1020
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $124K | ﹤0.01% |
+5,107
| New | +$174K |
|
|
KRON
1021
DELISTED
Kronos Bio
KRON
| $122K | ﹤0.01% |
33,651
-24,525
| -42% | -$111K |
|
1022
Kearny Financial
KRNY
$592M
| $116K | ﹤0.01% |
+10,414
| New | +$125K |
|
1023
Rigel Pharmaceuticals
RIGL
$680M
| $115K | ﹤0.01% |
10,207
-7,438
| -42% | -$149K |
|
1024
Acco Brands
ACCO
$369M
| $112K | ﹤0.01% |
17,090
+2,736
| +19% | +$19.9K |
|
|
CNCE
1025
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $112K | ﹤0.01% |
+26,665
| New | +$106K |
|
Similar funds
PAG
MMH
IC
DSA
VARA
SC
CB
ALPS Advisors's Q2 2022 Portfolio in Review
As of Q2 2022, ALPS Advisors held 1,109 positions worth $10.3B, up 12% from $9.22B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
ALPS Advisors deployed $2.36B of net new capital in Q2 2022, opening 276 new positions and adding to 252 existing holdings. Its largest new stake was Western Midstream Partners: 24,175,389 shares worth $588M.
By sector, the portfolio is most concentrated in Energy at 60% of assets, down from 66% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Energy Transfer Partners, an estimated $71M trimmed.
- ALPS Advisors's largest Q2 2022 buy was Western Midstream Partners: 24,175,389 shares worth $588M.
- ALPS Advisors added most to Hess Midstream in Q2 2022, an estimated $80.6M increase.
- ALPS Advisors's biggest Q2 2022 reduction was Energy Transfer Partners, cutting an estimated $71M.
- ALPS Advisors fully exited People's United Financial Inc in Q2 2022, selling an estimated $23.8M.
- ALPS Advisors's ten largest holdings make up 47% of its $10.3B portfolio in Q2 2022.
- ALPS Advisors opened 276 new positions and closed 79 in Q2 2022.
- ALPS Advisors's portfolio value rose 12% quarter-over-quarter to $10.3B.
Based on ALPS Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.